Gastric neoplasm

Researchers are comparing two ways of performing robotic surgery to remove stomach cancer: a single-port approach and a standard multi-port approach. The trial enrolls 212 adults with stomach cancer that can be removed with distal gastrectomy. The main question is whether the sin…

Researchers are testing whether adding zolbetuximab to standard chemotherapy is safe and helps control advanced stomach or gastroesophageal junction cancer in Indian patients. The trial enrolls 50 adults whose tumors carry the Claudin 18.2 protein but not HER2. Participants recei…

Researchers are running a first-in-human study of MGC030, an antibody-drug conjugate, in people with advanced solid tumors that have come back or stopped responding to standard treatment. The trial includes participants with urothelial, colorectal, gastric, gastroesophageal, esop…

Researchers are testing a combination of three drugs in adults with advanced gastric cancer that has grown after one standard chemotherapy regimen and whose tumors carry the PD-L1 protein. The drugs are irinotecan liposome (a chemotherapy wrapped in fat particles), fruquintinib (…

Researchers are testing whether adding an experimental drug called ONO-4578 to nivolumab and chemotherapy helps people with advanced or metastatic gastric cancer, esophagogastric junction cancer, or esophageal adenocarcinoma. The trial enrolls about 600 adults whose tumors are HE…

Researchers are testing a new drug called TS-104 in adults with advanced solid tumors, including lung, head and neck, ovarian, endometrial, esophageal, and gastric cancers. TS-104 is a peptide drug conjugate: it uses a targeting peptide to carry the chemotherapy drug MMAE directl…

This early-phase trial tests an oral drug called R01 in people with advanced squamous cell lung cancer, gastric cancer, or esophageal cancer that has progressed after standard treatment. The study aims to find the safest dose and check whether R01 can shrink tumors. Participants …

This early-stage trial tests an experimental drug called STRO-006 in adults with advanced solid tumors, including head and neck, lung, esophageal, gastric, colorectal, endometrial, bladder, and breast cancers that have not responded to standard treatments. The study has three par…

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This trial tests whether pembrolizumab, an immunotherapy drug, is safe when combined with chemotherapy or chemoradiotherapy for people in India with advanced gastric or gastroesophageal junction cancer, advanced biliary tract cancer, or high-risk locally advanced cervical cancer.…

This trial tests whether high-flow nasal cannula (HFNC) oxygen can reduce the risk of hypoxemia, or low blood oxygen, during sedated gastrointestinal endoscopy in patients with chronic obstructive pulmonary disease (COPD). COPD patients often have low oxygen reserves, making them…

This trial tests whether adding radical surgery to remove the stomach tumor and nearby lymph nodes improves survival and quality of life compared with continuing drug therapy alone in patients with stomach cancer that has spread to the abdominal lining (peritoneal metastasis) and…

This study looks at how zanidatamab, a targeted drug for HER2-positive gastroesophageal cancer, is used in real-world clinical practice. Researchers will track about 300 adults with advanced or metastatic disease who are starting zanidatamab as their first treatment, recording pa…

This study tests whether people with certain gastrointestinal cancers—like stomach, esophageal, or colorectal—can safely skip radical surgery after responding well to precision therapies such as immunotherapy or targeted drugs. Participants with specific molecular markers will be…

This phase II trial is testing whether adding a type of precise radiation called stereotactic body radiation therapy (SBRT) to standard immunotherapy can help people with stage IV cancers, including head and neck, lung, cervical, esophageal, and gastric cancers. Participants will…

This trial tests whether a single dose of ferric carboxymaltose can treat iron-deficiency anemia after stomach cancer surgery as effectively as multiple doses of iron sucrose. About 160 adults who had curative stomach cancer surgery and developed anemia will be randomly assigned …

This trial tests whether a home-based prehabilitation program, supported by 5G and artificial intelligence, can help gastric cancer patients prepare for surgery after chemotherapy. The program includes personalized exercise, nutrition, and psychological support, all supervised re…

This phase 2 trial tests giving short course radiation therapy along with standard chemotherapy before surgery for stomach cancer. The goal is to see if this total neoadjuvant therapy leads to a higher rate of complete cancer disappearance, with fewer side effects than traditiona…

This early-stage trial is testing an experimental treatment called the IKS04 regimen in people with advanced cancers of the digestive system, including colorectal, stomach, pancreatic, and bile duct cancers. The regimen combines a targeted antibody-drug conjugate with an addition…

This early-phase trial tests a new treatment for stomach cancer that has spread to the lining of the abdomen. Ten adults will receive specially engineered immune cells (NK cells) infused directly into the abdomen, along with standard chemotherapy drugs. The main goals are to find…

This trial tests whether a combination of whole-body electromyostimulation (WB-EMS) — a technology that uses electrical impulses to make muscles contract — and nutritional therapy can help people with certain gastrointestinal cancers preserve muscle mass. Participants include tho…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests whether adding an experimental drug called retlirafusp alfa to standard chemotherapy can shrink advanced stomach or gastroesophageal junction cancers enough to allow complete surgical removal. Participants receive the drug combination before surgery, and those wh…

This phase 3 trial tests whether adding an experimental drug called cadonilimab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. Cadonilimab is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) …

This phase 2 trial tests a combination of two drugs—becotatugvedotin (a targeted therapy that delivers a toxin directly to cancer cells) and pucotenlimab (an immunotherapy that helps the immune system attack cancer)—as a second-line treatment for people with advanced gastric or g…

This trial investigates whether adding the targeted antibody zanidatamab to standard chemotherapy can shrink HER2-positive stomach or gastroesophageal junction cancers before surgery. It includes two groups: people with locally advanced cancer that has not spread, and those with …

This phase 2 trial tests a combination of three drugs—sintilimab, ramucirumab, and paclitaxel—in 30 adults with HER2-negative stomach cancer that came back during or within 6 months of finishing adjuvant therapy. The main goal is to see how many patients' tumors shrink significan…

This phase 2 trial tests whether adding the targeted drug fruquintinib to standard immunotherapy (sintilimab) and chemotherapy (SOX) can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 120 participants will receive either the t…

This study looks at whether immunotherapy can shrink certain gastrointestinal cancers (like colorectal or stomach cancer) enough that some patients may not need major surgery. People whose tumors have specific genetic features (MSI-H/dMMR or POLE mutation) and who respond well to…

This phase 2 trial tests a combination of four drugs—mannatide, two chemotherapy drugs, and an immunotherapy—as a first treatment for people with advanced stomach or gastroesophageal junction cancer that has spread or come back. The study will enroll 52 participants to see if the…

This study tests a combination of the immunotherapy drug sintilimab and a chemotherapy regimen called FOLFIRI as a second-line treatment for people with advanced HER2-negative stomach cancer that has progressed after initial therapy. The goal is to see if this approach can delay …

This study tests a procedure called calcium electroporation to stop bleeding from stomach cancer tumors. Doctors inject calcium into the tumor and use a special device to deliver small electrical pulses, which can help control bleeding. The trial will include 28 patients with adv…

This study looks at whether people with certain genetic types of gastrointestinal cancers (stomach, colorectal, or anal) can safely avoid major surgery after immunotherapy. Instead of removing the organ, doctors will monitor closely or do smaller procedures to remove any remainin…

This study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…

This study tests whether adding sodium propionate, a common food preservative, to standard immunotherapy and chemotherapy can improve tumor shrinkage in people with advanced stomach cancer. About 20 adults with inoperable gastric cancer will be randomly assigned to receive either…

This study looks at whether changing the type of chemotherapy after stomach cancer surgery can help people live longer. It involves 405 adults who had chemotherapy and immunotherapy before surgery. Depending on how much cancer remained after surgery, some will get a different tre…

This phase 2 trial tests a new immunotherapy drug called iparomlimab tolvorlimab (QL1706) in 30 people with a specific type of locally advanced stomach cancer (MSI-H/dMMR). The drug is given before and after surgery to see if it can eliminate the tumor. The main goal is to see ho…

This study looks at whether adding a common blood pressure medication (beta-blocker) to standard immunotherapy can help shrink stomach cancer before surgery. It will include 33 adults with high blood pressure and locally advanced stomach cancer. The goal is to see if the combinat…

This study tests a combination of three drugs (sintilimab, bevacizumab, and chemotherapy) in people with a rare and aggressive type of stomach cancer that produces a protein called AFP. The goal is to shrink the tumors enough so they can be surgically removed. About 46 adults wit…

This clinical trial is testing a new approach for people with advanced HER2-negative stomach or gastroesophageal junction cancer that cannot be removed by surgery. The treatment combines two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (SOX) and a…

This study looks at whether adding sucralfate (a protective coating agent) to standard esomeprazole (a stomach acid reducer) helps heal artificial ulcers created during endoscopic surgery for early stomach cancer or precancerous growths. About 120 adults will be randomly assigned…

This study compares two types of minimally invasive surgery for early-stage stomach cancer: a newer robotic method using fewer incisions (reduced-port) and the standard laparoscopic method. About 538 patients will be randomly assigned to one of the two surgeries. The main goal is…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests a combination of two drugs—CVL237 tablets and serplulimab injection—in people with advanced solid tumors that have lost or have low levels of a protein called PTEN. The trial aims to find the safest dose and see if the combo can shrink tumors or delay their growt…

This study tests whether adding the drug ivonescimab to standard chemotherapy (SOX) can better shrink or eliminate tumors in people with locally advanced stomach or gastroesophageal junction cancer before surgery. About 154 adults aged 18-75 will be randomly assigned to receive e…

This study tests a new drug called JPI-547 combined with irinotecan for people with advanced stomach cancer that has come back or spread after at least two prior treatments. The goal is to see if the combination is safe and can shrink tumors. About 49 adults with good performance…

This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…

This study tests if robot-assisted surgery helps people with a certain type of stomach cancer live longer without the cancer coming back, compared to standard laparoscopy. About 335 adults aged 18-80 with stage cT4a stomach cancer will be randomly assigned to one of the two surgi…

This early-stage trial tests a new treatment called AB-201 for advanced HER2-positive stomach or gastroesophageal junction cancer. AB-201 uses specially engineered natural killer cells to target and kill cancer cells. The study will enroll 18 adults whose cancer has not responded…

This early-stage trial tests a new type of cell therapy called CAR-T cells that are designed to target two proteins (CD73 and AXL) found on stomach cancer cells. The study will enroll 42 people with stage IV stomach cancer that has not responded to standard treatments. The main g…

This Phase 3 trial tests whether adding an immunotherapy drug (adebrelimab) and a targeted therapy (apatinib) to standard chemotherapy (SOX) can improve outcomes for people with locally advanced stomach cancer that cannot be removed right away. The study will enroll 118 participa…

This Phase II trial tests whether adding a new immunotherapy drug (QL1706) to standard chemotherapy (SOX) before surgery can completely eliminate stomach cancer in patients with a specific, aggressive type. About 74 adults with stage III diffuse-type gastric cancer will be random…

This study tests a less invasive surgical approach for people with early gastric cancer who need additional treatment after an initial endoscopic removal. The procedure uses a special dye to guide removal of nearby lymph nodes, with or without removing a small part of the stomach…

This study tests a new drug called TST001 added to standard chemotherapy and immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination helps control the tumor longer and improves surv…

This study compares a new, less invasive surgery that removes only the cancerous upper part of the stomach to the standard full stomach removal. The goal is to see if the new approach helps patients lose less weight one year after surgery. The trial will enroll 120 adults with ea…

This study tests whether a family-supervised program combining exercise, nutrition advice, and psychological support can reduce complications after stomach cancer surgery. About 90 adults who will receive chemotherapy before surgery are randomly assigned to either the program plu…

This clinical trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy (albumin-bound paclitaxel) as a second-line treatment for advanced stomach or gastroesophageal junction cancer. The study will enroll 30 adults whose cancer has wor…

This early-phase trial will test NK510, a cell therapy, in 15 people with advanced stomach or colorectal cancer that has come back or not responded to at least two prior treatments. NK510 is given through an IV or directly into the abdomen. The main goals are to check safety and …

This is the first human study of an experimental cancer drug called M7437, which targets a specific protein found on certain tumor cells. The study will test the safety, side effects, and early effectiveness of M7437 in 138 people with advanced solid tumors that have stopped resp…

Many cancer trials require patients to have specific molecular markers, so researchers test large numbers of people to find the few who qualify. This study evaluates FATHOM, an AI system that reads clinical trial records and routine tumor slides to predict which patients carry th…

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This trial is testing whether a new blood test that looks at DNA in red blood cells, aided by artificial intelligence, can accurately detect stomach cancer. It will involve about 542 adults scheduled for an upper endoscopy to check for stomach conditions. The test's accuracy will…

This study tests a new imaging tracer called [18F]FAPI-74, which attaches to a protein found on cells in tumors and scarred or inflamed tissue. Researchers want to see if it can show these areas more clearly than current scans. About 770 adults with various cancers or non-cancer …

This study tests whether a special ultrasound technique, called contrast-enhanced subharmonic ultrasound, can predict if chemotherapy is working for stomach cancer that has spread to the liver. Currently, doctors wait about 2 months for CT or MRI scans to see tumor shrinkage. Thi…

This study tests a new PET imaging tracer, [68Ga]Ga-NODAGA-SNA014, to detect a protein called Claudin18.2 in pancreatic and stomach cancers. The goal is to see if the scan can accurately identify patients whose tumors have this protein, which could help doctors choose the right t…

This study will test whether combining a special PET scan (18F-FAPI) with detailed MRI can better detect stomach cancer and its spread. Researchers will compare the accuracy of these scans in 230 people with suspected or confirmed gastric cancer. The goal is to see if this combo …

This study looks at whether a special microscope on a thin probe (pCLE) can better detect early stomach cancer than the usual biopsy method. Researchers will review past cases from 169 patients who had both tests. The goal is to see which method is more sensitive and accurate, wh…

This study explores a new way to diagnose gastric cancer by analyzing tiny particles called extracellular vesicles found in stomach fluid. Researchers will collect stomach fluid from 100 patients undergoing gastroscopy and use a special sensor to detect cancer-related changes. Th…

This study tests a new, less invasive way to screen for stomach cancer using a magnetic-guided video capsule that patients swallow. The capsule is steered by a robot and uses AI to check the stomach for suspicious spots. Researchers will compare its accuracy to standard endoscopy…

This study tests a new fluorescent dye that attaches to cancer cells, helping surgeons see exactly where a stomach tumor ends during surgery. The probe is tested on freshly removed stomach tissue from 32 patients. If successful, it could lead to more precise cancer removal and fe…

This study will develop and test a diagnostic model to help doctors identify early gastric cancer during endoscopy. Researchers will use a special imaging technique called narrow band imaging (NBI) to examine suspicious lesions in 300 patients aged 40-80. The goal is to improve a…

This study tests a new radioactive imaging agent called 68Ga-NOTA-GPA33 nanobody, which targets a protein (GPA33) found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage colorectal, stomach, and pancreatic cancers in 56 patients…

This study tests whether finding and treating a high-risk type of H. pylori bacteria can prevent stomach cancer. Over 4,800 adults aged 40 and older will be assigned to either standard care or a program that screens for risky H. pylori subtypes and offers antibiotic treatment. Re…

Researchers are studying whether a procedure called fluoroscopy-guided transdiscal splanchnic nerve neurolysis can safely reduce severe upper abdominal pain in adults with pancreatic, gastric, or hepatobiliary cancer. Participants first receive a diagnostic nerve block with local…

This study tests whether a low dose of olanzapine, a drug often used for nausea, can help gastric cancer patients avoid weight loss and keep their appetite during chemotherapy before surgery. About 26 adults with stomach cancer will be randomly assigned to receive olanzapine or s…

This trial tests whether a home-based, digitally supervised prehabilitation program—using 5G and AI—can help gastric cancer patients get fitter before surgery. Participants who have completed chemotherapy and are scheduled for stomach removal will either receive standard care or …

This study explores whether a personalized music therapy session, called music-assisted relaxation and imagery (MARI), can reduce pain and change gene activity in people recovering from open surgery for stomach, pancreas, bile duct, liver, or peritoneal cancer. Participants will …

This study tests a digital tool called RECapp that helps patients recover after surgery for esophageal or stomach cancer. The app lets patients track symptoms, get personalized self-care advice, and know when to contact their healthcare team. 250 adults in Sweden will use the app…

This trial tests whether a nurse-led program combining an AI chatbot and home-based exercises can help advanced gastric cancer patients on immunotherapy feel less frail and have a better quality of life. Participants use the chatbot to report side effects and get personalized adv…

This study tests whether transcutaneous electrical acupoint stimulation (TEAS) — a needle-free treatment that sends mild electrical pulses through sticky pads on the skin — can help people recover faster after laparoscopic surgery for stomach cancer. Researchers are comparing thr…

This trial compares a fixed-dose combination of acetaminophen and ibuprofen (Maxigesic) against acetaminophen alone for pain relief after minimally invasive stomach cancer surgery. 160 adults scheduled for radical gastrectomy will receive either the combo or standard acetaminophe…

This study tests whether a home-based exercise program can help people with gastrointestinal or lung cancer handle chemotherapy better. Up to 120 participants will be randomly assigned to either an aerobic and resistance exercise group or a stretching group. All activities are do…

This study tests two methods to reduce pain after keyhole stomach surgery for cancer. One method uses a standard ultrasound-guided nerve block, while the other applies a special temperature-sensitive gel mixed with numbing medicine directly to the surgical site. The goal is to se…

This study tests whether a drug called megestrol acetate can help prevent weight loss in people with stage III stomach cancer who are about to have surgery. About 48 participants will receive either standard treatment (chemoimmunotherapy) or standard treatment plus megestrol acet…

This study tests a 'peri-habilitation' program for 30 gastric cancer patients aged 65 and older. Participants receive nutrition education and protein-enriched soy milk for two weeks before surgery, plus exercise training and continued nutrition support for three weeks after leavi…

This study follows 328 adults aged 60 and older who are having surgery for gastric cancer. Researchers will measure frailty, nutrition, and muscle mass before surgery, then track complications, delirium, and recovery afterward. The goal is to see whether these factors, along with…

This observational study tracks how patients with stage II to IVB gastric or gastroesophageal junction cancer are actually treated in routine clinical practice across Greece. Researchers will collect data on patient characteristics, treatment choices, timing of therapies, and bio…

This study asks whether an artificial intelligence system can make the same care recommendations as a team of cancer experts for people with stomach, colon, or rectal cancer. About 69 participants will have their medical information reviewed independently by both the AI and a mul…

This study is testing whether artificial intelligence can predict how well stomach cancer patients will respond to chemotherapy given before surgery. Researchers will collect CT scans, ultrasound images, and blood samples from 300 patients with locally advanced gastric cancer. Us…

This study tests a new one-click autofocus system for magnifying endoscopy, which uses computer vision to automatically focus the camera during stomach exams. Researchers will compare it to the standard manual focus method in 93 patients with stomach diseases. The goal is to see …

This study looks at how often polyps in the stomach or colon grow back after being removed during a scope procedure. Researchers will follow about 2,000 adults for up to three years to track recurrence and identify risk factors like polyp size, lifestyle, and health history. The …

This study will collect data from 10,000 people undergoing upper endoscopy to build an AI model that predicts the risk of developing stomach or esophageal cancer. Researchers will combine information from endoscopy images, tissue samples, genetics, and gut bacteria. Participants …

This study looks at whether tumor DNA found in blood or peritoneal fluid can predict the spread of digestive cancers (stomach, colon, pancreas) to the lining of the abdomen. Researchers will follow 300 patients with early-stage tumors to see if those with positive DNA markers are…

This study tests whether a personalized blood test (Signatera) can identify gastric cancer patients who, after surgery, have no detectable cancer DNA and can safely receive a milder immunotherapy (durvalumab) instead of standard chemotherapy. About 1000 adults with stage II-IVa g…

This study tests whether using MRI scans to plan radiotherapy is better than using CT scans alone. Researchers will work with up to 150 cancer patients and 15 healthy volunteers to see if MRI can make treatment more precise and reduce side effects. The goal is to improve how tumo…

This study looks at whether a simple blood test can help doctors decide the best treatment after surgery for stomach or gastroesophageal junction cancer. About 32 people with stage III or IVA cancer will give blood samples before and after surgery to check for tumor DNA. The goal…

This study looks at whether a blood test for circulating tumor DNA (ctDNA) can detect leftover cancer after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 participants will give blood samples before and after standard treatments. No new treat…